Share Price and Basic Stock Data
Last Updated: February 14, 2026, 9:16 pm
| PEG Ratio | 2.89 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Procter & Gamble Health Ltd operates within the pharmaceuticals sector, focusing on health and wellness products. As of October 2023, the company’s share price stood at ₹5,483, with a market capitalization of ₹9,082 Cr. The firm reported a total revenue of ₹1,230 Cr for the fiscal year ending June 2023, showing a steady growth trajectory from ₹1,114 Cr in June 2022. Revenue growth has been supported by quarterly sales figures, with the latest recorded sales for September 2023 at ₹305 Cr, up from ₹301 Cr in June 2023. However, the revenue figures for March 2024 and June 2024 indicate a temporary decline, with sales dropping to ₹252 Cr and ₹284 Cr, respectively, before rebounding to ₹313 Cr in September 2024. This suggests a seasonal impact or potential market fluctuations affecting sales performance. Overall, the revenue performance illustrates the company’s resilience and its ability to navigate market challenges.
Profitability and Efficiency Metrics
Procter & Gamble Health demonstrated strong profitability metrics, with a reported net profit of ₹307 Cr and a profit margin of approximately 25.09% for the trailing twelve months. The operating profit margin (OPM) stood at 37%, showcasing effective cost management relative to sales. The company’s return on equity (ROE) was a remarkable 36.4%, indicating efficient use of shareholder equity to generate profits. The interest coverage ratio (ICR) was exceptionally high at 446.71x, reflecting the company’s robust ability to meet interest obligations with its earnings. Despite experiencing fluctuations in operating profit across quarters, the company consistently managed to maintain positive operating profits, with a notable recovery in September 2024, where OPM rose to 36%. These metrics highlight P&G Health’s operational efficiency and its strategic management of expenses, contributing positively to its financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Procter & Gamble Health Ltd reflects a solid financial position, with total reserves reported at ₹603 Cr and minimal borrowings of ₹6 Cr. The company’s current ratio stood at 2.44, indicating a strong liquidity position and the ability to cover short-term liabilities comfortably. The price-to-book value (P/BV) ratio was recorded at 15.57x, suggesting that the market values the company highly relative to its book value. Additionally, Procter & Gamble Health’s return on capital employed (ROCE) was impressive at 47.8%, signifying effective capital utilization to generate profits. The cash conversion cycle was negative at -30 days, indicating that the company efficiently manages its working capital, turning over inventory and receivables faster than it pays its suppliers. Overall, these financial ratios underscore the company’s strong balance sheet and operational effectiveness.
Shareholding Pattern and Investor Confidence
The shareholding structure of Procter & Gamble Health Ltd showcases a balanced distribution, with promoters holding 51.82% of the shares, signifying strong control and commitment to the company’s long-term vision. Foreign institutional investors (FIIs) accounted for 7.24% of the holdings, while domestic institutional investors (DIIs) held 13.90%. The public segment comprised 27.05%, with a total of 50,006 shareholders as of September 2025. The gradual increase in FII participation from 6.33% in December 2022 to 7.24% suggests growing confidence among international investors in the company’s potential. However, the decline in the number of shareholders from 63,831 in December 2022 to 50,006 indicates a consolidation that may stem from strategic realignments or market conditions. This evolving shareholding pattern reflects a combination of investor confidence and market dynamics.
Outlook, Risks, and Final Insight
Procter & Gamble Health Ltd is positioned well for continued growth, supported by strong profitability metrics and a robust balance sheet. However, the company faces risks, including potential fluctuations in sales due to market conditions and the impact of competition within the pharmaceuticals sector. The recent dip in sales figures for March and June 2024 may pose short-term challenges that require strategic management. Additionally, the high P/BV ratio could indicate overvaluation concerns if the company fails to sustain its growth trajectory. Looking ahead, the firm must leverage its operational strengths and address market volatility to maintain its competitive edge. If the company can navigate these challenges effectively, it stands to benefit from increasing demand in the health and wellness sector, positioning it for long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 129 Cr. | 103 | 137/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.15/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,402 Cr. | 312 | 479/192 | 71.2 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 28.3 Cr. | 38.2 | 79.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 84.4 Cr. | 57.6 | 57.6/17.0 | 338 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,956.81 Cr | 1,098.00 | 54.79 | 201.74 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 298 | 310 | 321 | 301 | 305 | 310 | 252 | 284 | 313 | 310 | 311 | 339 | 325 |
| Expenses | 207 | 201 | 241 | 256 | 216 | 208 | 185 | 236 | 199 | 186 | 230 | 248 | 205 |
| Operating Profit | 91 | 109 | 80 | 45 | 89 | 102 | 67 | 48 | 114 | 123 | 81 | 90 | 120 |
| OPM % | 31% | 35% | 25% | 15% | 29% | 33% | 27% | 17% | 36% | 40% | 26% | 27% | 37% |
| Other Income | 3 | 5 | 5 | 5 | 6 | 5 | 2 | -18 | 3 | 4 | 3 | 4 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 7 | 8 | 6 | 6 | 6 | 7 | 7 | 7 | 6 | 6 | 5 | 5 | 6 |
| Profit before tax | 87 | 105 | 79 | 44 | 88 | 100 | 63 | 23 | 111 | 122 | 79 | 89 | 119 |
| Tax % | 26% | 27% | 25% | 32% | 26% | 28% | 26% | 26% | 26% | 25% | 22% | 25% | 26% |
| Net Profit | 64 | 77 | 59 | 30 | 66 | 72 | 47 | 17 | 82 | 91 | 61 | 66 | 89 |
| EPS in Rs | 38.35 | 46.27 | 35.66 | 17.96 | 39.50 | 43.42 | 28.05 | 10.11 | 49.60 | 54.76 | 36.86 | 39.87 | 53.34 |
Last Updated: December 29, 2025, 12:05 pm
Below is a detailed analysis of the quarterly data for Procter & Gamble Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 325.00 Cr.. The value appears to be declining and may need further review. It has decreased from 339.00 Cr. (Jun 2025) to 325.00 Cr., marking a decrease of 14.00 Cr..
- For Expenses, as of Sep 2025, the value is 205.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 248.00 Cr. (Jun 2025) to 205.00 Cr., marking a decrease of 43.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 120.00 Cr.. The value appears strong and on an upward trend. It has increased from 90.00 Cr. (Jun 2025) to 120.00 Cr., marking an increase of 30.00 Cr..
- For OPM %, as of Sep 2025, the value is 37.00%. The value appears strong and on an upward trend. It has increased from 27.00% (Jun 2025) to 37.00%, marking an increase of 10.00%.
- For Other Income, as of Sep 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 4.00 Cr. (Jun 2025) to 5.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5.00 Cr. (Jun 2025) to 6.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 119.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Jun 2025) to 119.00 Cr., marking an increase of 30.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 25.00% (Jun 2025) to 26.00%, marking an increase of 1.00%.
- For Net Profit, as of Sep 2025, the value is 89.00 Cr.. The value appears strong and on an upward trend. It has increased from 66.00 Cr. (Jun 2025) to 89.00 Cr., marking an increase of 23.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 53.34. The value appears strong and on an upward trend. It has increased from 39.87 (Jun 2025) to 53.34, marking an increase of 13.47.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:47 am
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 867 | 940 | 993 | 698 | 849 | 927 | 1,356 | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,284 |
| Expenses | 809 | 855 | 877 | 621 | 701 | 723 | 1,037 | 762 | 846 | 905 | 845 | 616 | 869 |
| Operating Profit | 59 | 85 | 116 | 77 | 148 | 204 | 319 | 246 | 268 | 325 | 307 | 319 | 415 |
| OPM % | 7% | 9% | 12% | 11% | 17% | 22% | 24% | 24% | 24% | 26% | 27% | 34% | 32% |
| Other Income | 20 | 22 | 24 | 74 | 768 | 48 | 66 | 18 | 13 | 18 | -5 | 10 | 16 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
| Depreciation | 13 | 23 | 25 | 19 | 21 | 17 | 29 | 30 | 27 | 28 | 27 | 17 | 22 |
| Profit before tax | 67 | 83 | 115 | 132 | 895 | 234 | 355 | 233 | 253 | 314 | 273 | 312 | 408 |
| Tax % | 35% | 36% | 31% | 29% | 6% | 32% | 28% | 24% | 24% | 27% | 26% | 25% | |
| Net Profit | 43 | 54 | 79 | 94 | 839 | 159 | 254 | 177 | 193 | 229 | 201 | 234 | 307 |
| EPS in Rs | 26.04 | 32.27 | 47.67 | 56.57 | 505.27 | 95.64 | 153.07 | 106.51 | 115.98 | 138.24 | 121.08 | 141.22 | 184.83 |
| Dividend Payout % | 23% | 23% | 23% | 27% | 87% | 0% | 150% | 122% | 45% | 69% | 215% | 89% |
YoY Net Profit Growth
| Year |
|---|
| YoY Net Profit Growth (%) |
| Change in YoY Net Profit Growth (%) |
No data available for trend analysis.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 0% |
| 3 Years: | -3% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 8% |
| 3 Years: | 10% |
| TTM: | 43% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 6% |
| 3 Years: | 14% |
| 1 Year: | 24% |
| Return on Equity | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 27% |
| 3 Years: | 33% |
| Last Year: | 36% |
Last Updated: September 5, 2025, 12:40 pm
Balance Sheet
Last Updated: February 1, 2026, 3:46 am
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 17 |
| Reserves | 538 | 575 | 647 | 717 | 1,524 | 800 | 890 | 687 | 600 | 734 | 522 | 520 | 603 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 3 | 12 | 10 | 8 | 6 |
| Other Liabilities | 154 | 192 | 215 | 258 | 219 | 250 | 269 | 275 | 269 | 338 | 247 | 250 | 268 |
| Total Liabilities | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
| Fixed Assets | 110 | 132 | 111 | 115 | 104 | 101 | 101 | 104 | 112 | 144 | 128 | 116 | 106 |
| CWIP | 28 | 7 | 30 | 9 | 17 | 11 | 21 | 39 | 41 | 32 | 6 | 11 | 13 |
| Investments | 24 | 42 | 28 | 70 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 547 | 603 | 711 | 797 | 1,639 | 954 | 1,053 | 843 | 736 | 925 | 660 | 667 | 776 |
| Total Assets | 708 | 784 | 879 | 991 | 1,759 | 1,067 | 1,176 | 986 | 888 | 1,101 | 794 | 794 | 894 |
Below is a detailed analysis of the balance sheet data for Procter & Gamble Health Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 17.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 17.00 Cr..
- For Reserves, as of Sep 2025, the value is 603.00 Cr.. The value appears strong and on an upward trend. It has increased from 520.00 Cr. (Mar 2025) to 603.00 Cr., marking an increase of 83.00 Cr..
- For Borrowings, as of Sep 2025, the value is 6.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 2.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 268.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 250.00 Cr. (Mar 2025) to 268.00 Cr., marking an increase of 18.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 894.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 106.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 106.00 Cr., marking a decrease of 10.00 Cr..
- For CWIP, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 11.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 776.00 Cr.. The value appears strong and on an upward trend. It has increased from 667.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 109.00 Cr..
- For Total Assets, as of Sep 2025, the value is 894.00 Cr.. The value appears strong and on an upward trend. It has increased from 794.00 Cr. (Mar 2025) to 894.00 Cr., marking an increase of 100.00 Cr..
Notably, the Reserves (603.00 Cr.) exceed the Borrowings (6.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020n n 18m | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025n n 16m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 59.00 | 85.00 | 116.00 | 77.00 | 148.00 | 204.00 | 319.00 | 238.00 | 265.00 | 313.00 | 297.00 | 319.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 49 | 39 | 64 | 28 | 30 | 26 | 22 | 27 | 34 | 27 | 57 |
| Inventory Days | 162 | 140 | 145 | 243 | 154 | 139 | 113 | 138 | 124 | 136 | 120 | 152 |
| Days Payable | 40 | 55 | 67 | 128 | 124 | 106 | 105 | 209 | 185 | 239 | 184 | 239 |
| Cash Conversion Cycle | 166 | 134 | 118 | 179 | 58 | 63 | 34 | -49 | -34 | -69 | -37 | -30 |
| Working Capital Days | 74 | 69 | 52 | 94 | 42 | 22 | 23 | 7 | 17 | 15 | 19 | 48 |
| ROCE % | 12% | 15% | 18% | 16% | 78% | 20% | 29% | 29% | 38% | 45% | 45% | 48% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Nippon India Small Cap Fund | 692,659 | 0.58 | 395.02 | 596,807 | 2025-12-08 07:42:13 | 16.06% |
| ICICI Prudential Smallcap Fund | 362,766 | 2.45 | 206.89 | 360,975 | 2026-01-26 08:54:41 | 0.5% |
| UTI MNC Fund | 229,559 | 4.58 | 130.92 | 240,895 | 2025-12-14 02:16:25 | -4.71% |
| DSP Healthcare Fund | 159,288 | 2.92 | 90.84 | 158,704 | 2025-12-07 19:34:14 | 0.37% |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 71,471 | 0.63 | 40.76 | N/A | N/A | N/A |
| Aditya Birla Sun Life MNC Fund | 69,716 | 1.11 | 39.76 | N/A | N/A | N/A |
| UTI Healthcare Fund | 66,803 | 3.46 | 38.1 | 67,014 | 2026-01-25 11:07:48 | -0.31% |
| ICICI Prudential Bharat Consumption Fund | 22,192 | 0.39 | 12.66 | 22,442 | 2026-01-25 11:07:48 | -1.11% |
| Aditya Birla Sun Life Pharma & Healthcare Fund | 19,000 | 1.29 | 10.84 | N/A | N/A | N/A |
| UTI Balance Advantage Fund | 15,271 | 0.27 | 8.71 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Jun 24 | Jun 23 | Jun 22 | Jun 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 141.00 | 133.00 | 138.00 | 116.00 | 107.00 |
| Diluted EPS (Rs.) | 141.00 | 121.00 | 138.00 | 116.00 | 107.00 |
| Cash EPS (Rs.) | 151.26 | 137.58 | 155.16 | 132.29 | 124.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 323.47 | 324.24 | 452.34 | 371.38 | 423.92 |
| Dividend / Share (Rs.) | 125.00 | 260.00 | 95.00 | 52.50 | 130.00 |
| Revenue From Operations / Share (Rs.) | 562.75 | 693.53 | 740.73 | 671.33 | 607.67 |
| PBDIT / Share (Rs.) | 198.04 | 193.75 | 206.67 | 169.20 | 159.11 |
| PBIT / Share (Rs.) | 187.98 | 177.25 | 189.74 | 152.88 | 141.01 |
| PBT / Share (Rs.) | 187.72 | 164.65 | 189.28 | 152.63 | 140.53 |
| Net Profit / Share (Rs.) | 141.21 | 121.07 | 138.23 | 115.97 | 106.51 |
| PBDIT Margin (%) | 35.19 | 27.93 | 27.90 | 25.20 | 26.18 |
| PBIT Margin (%) | 33.40 | 25.55 | 25.61 | 22.77 | 23.20 |
| PBT Margin (%) | 33.35 | 23.74 | 25.55 | 22.73 | 23.12 |
| Net Profit Margin (%) | 25.09 | 17.45 | 18.66 | 17.27 | 17.52 |
| Return on Networth / Equity (%) | 43.65 | 37.34 | 30.55 | 31.22 | 25.12 |
| Return on Capital Employeed (%) | 53.90 | 51.13 | 39.50 | 38.57 | 31.32 |
| Return On Assets (%) | 29.51 | 25.30 | 20.83 | 21.54 | 17.92 |
| Asset Turnover Ratio (%) | 1.18 | 1.21 | 1.23 | 1.19 | 0.93 |
| Current Ratio (X) | 2.44 | 2.39 | 2.62 | 2.60 | 3.04 |
| Quick Ratio (X) | 1.94 | 1.90 | 2.18 | 2.11 | 2.55 |
| Inventory Turnover Ratio (X) | 8.55 | 2.38 | 2.55 | 2.77 | 2.29 |
| Dividend Payout Ratio (NP) (%) | 99.14 | 206.48 | 40.87 | 147.43 | 215.93 |
| Dividend Payout Ratio (CP) (%) | 92.55 | 181.71 | 36.41 | 129.25 | 184.57 |
| Earning Retention Ratio (%) | 0.86 | -106.48 | 59.13 | -47.43 | -115.93 |
| Cash Earning Retention Ratio (%) | 7.45 | -81.71 | 63.59 | -29.25 | -84.57 |
| Interest Coverage Ratio (X) | 764.51 | 446.71 | 445.55 | 668.74 | 330.15 |
| Interest Coverage Ratio (Post Tax) (X) | 546.14 | 308.18 | 299.01 | 459.38 | 222.00 |
| Enterprise Value (Cr.) | 8347.67 | 8138.39 | 8273.45 | 6626.39 | 8817.13 |
| EV / Net Operating Revenue (X) | 8.94 | 7.07 | 6.73 | 5.95 | 8.74 |
| EV / EBITDA (X) | 25.39 | 25.30 | 24.12 | 23.59 | 33.38 |
| MarketCap / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| Retention Ratios (%) | 0.85 | -106.48 | 59.12 | -47.43 | -115.93 |
| Price / BV (X) | 15.90 | 15.57 | 11.60 | 11.28 | 13.20 |
| Price / Net Operating Revenue (X) | 9.14 | 7.28 | 7.09 | 6.24 | 9.21 |
| EarningsYield | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
After reviewing the key financial ratios for Procter & Gamble Health Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Jun 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 133.00 (Jun 24) to 141.00, marking an increase of 8.00.
- For Diluted EPS (Rs.), as of Mar 25, the value is 141.00. This value is within the healthy range. It has increased from 121.00 (Jun 24) to 141.00, marking an increase of 20.00.
- For Cash EPS (Rs.), as of Mar 25, the value is 151.26. This value is within the healthy range. It has increased from 137.58 (Jun 24) to 151.26, marking an increase of 13.68.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Jun 24) to 323.47, marking a decrease of 0.77.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 323.47. It has decreased from 324.24 (Jun 24) to 323.47, marking a decrease of 0.77.
- For Dividend / Share (Rs.), as of Mar 25, the value is 125.00. This value exceeds the healthy maximum of 3. It has decreased from 260.00 (Jun 24) to 125.00, marking a decrease of 135.00.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 562.75. It has decreased from 693.53 (Jun 24) to 562.75, marking a decrease of 130.78.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 198.04. This value is within the healthy range. It has increased from 193.75 (Jun 24) to 198.04, marking an increase of 4.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 187.98. This value is within the healthy range. It has increased from 177.25 (Jun 24) to 187.98, marking an increase of 10.73.
- For PBT / Share (Rs.), as of Mar 25, the value is 187.72. This value is within the healthy range. It has increased from 164.65 (Jun 24) to 187.72, marking an increase of 23.07.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 141.21. This value is within the healthy range. It has increased from 121.07 (Jun 24) to 141.21, marking an increase of 20.14.
- For PBDIT Margin (%), as of Mar 25, the value is 35.19. This value is within the healthy range. It has increased from 27.93 (Jun 24) to 35.19, marking an increase of 7.26.
- For PBIT Margin (%), as of Mar 25, the value is 33.40. This value exceeds the healthy maximum of 20. It has increased from 25.55 (Jun 24) to 33.40, marking an increase of 7.85.
- For PBT Margin (%), as of Mar 25, the value is 33.35. This value is within the healthy range. It has increased from 23.74 (Jun 24) to 33.35, marking an increase of 9.61.
- For Net Profit Margin (%), as of Mar 25, the value is 25.09. This value exceeds the healthy maximum of 10. It has increased from 17.45 (Jun 24) to 25.09, marking an increase of 7.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 43.65. This value is within the healthy range. It has increased from 37.34 (Jun 24) to 43.65, marking an increase of 6.31.
- For Return on Capital Employeed (%), as of Mar 25, the value is 53.90. This value is within the healthy range. It has increased from 51.13 (Jun 24) to 53.90, marking an increase of 2.77.
- For Return On Assets (%), as of Mar 25, the value is 29.51. This value is within the healthy range. It has increased from 25.30 (Jun 24) to 29.51, marking an increase of 4.21.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.18. It has decreased from 1.21 (Jun 24) to 1.18, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 2.44. This value is within the healthy range. It has increased from 2.39 (Jun 24) to 2.44, marking an increase of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.94. This value is within the healthy range. It has increased from 1.90 (Jun 24) to 1.94, marking an increase of 0.04.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 8.55. This value exceeds the healthy maximum of 8. It has increased from 2.38 (Jun 24) to 8.55, marking an increase of 6.17.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 99.14. This value exceeds the healthy maximum of 50. It has decreased from 206.48 (Jun 24) to 99.14, marking a decrease of 107.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 92.55. This value exceeds the healthy maximum of 50. It has decreased from 181.71 (Jun 24) to 92.55, marking a decrease of 89.16.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.86. This value is below the healthy minimum of 40. It has increased from -106.48 (Jun 24) to 0.86, marking an increase of 107.34.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 7.45. This value is below the healthy minimum of 40. It has increased from -81.71 (Jun 24) to 7.45, marking an increase of 89.16.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 764.51. This value is within the healthy range. It has increased from 446.71 (Jun 24) to 764.51, marking an increase of 317.80.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 546.14. This value is within the healthy range. It has increased from 308.18 (Jun 24) to 546.14, marking an increase of 237.96.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8,347.67. It has increased from 8,138.39 (Jun 24) to 8,347.67, marking an increase of 209.28.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.94. This value exceeds the healthy maximum of 3. It has increased from 7.07 (Jun 24) to 8.94, marking an increase of 1.87.
- For EV / EBITDA (X), as of Mar 25, the value is 25.39. This value exceeds the healthy maximum of 15. It has increased from 25.30 (Jun 24) to 25.39, marking an increase of 0.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Jun 24) to 9.14, marking an increase of 1.86.
- For Retention Ratios (%), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 30. It has increased from -106.48 (Jun 24) to 0.85, marking an increase of 107.33.
- For Price / BV (X), as of Mar 25, the value is 15.90. This value exceeds the healthy maximum of 3. It has increased from 15.57 (Jun 24) to 15.90, marking an increase of 0.33.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 9.14. This value exceeds the healthy maximum of 3. It has increased from 7.28 (Jun 24) to 9.14, marking an increase of 1.86.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. There is no change compared to the previous period (Jun 24) which recorded 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Procter & Gamble Health Ltd:
- Net Profit Margin: 25.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 53.9% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 43.65% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 546.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 28.2 (Industry average Stock P/E: 54.79)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 25.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | P&G Plaza, Cardinal Gracias Road, Mumbai Maharashtra 400009 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. S Madhavan | Chairman & Ind.Director |
| Mr. Milind Thatte | Managing Director |
| Mr. Lokesh Chandak | Executive Director & CFO |
| Ms. Seema Sambasivan | Non Executive Director |
| Mr. Aalok Agrawal | Non Executive Director |
| Ms. Krishna Sarma | Independent Director |
| Mr. Sharad Tyagi | Independent Director |
FAQ
What is the intrinsic value of Procter & Gamble Health Ltd?
Procter & Gamble Health Ltd's intrinsic value (as of 16 February 2026) is ₹3446.62 which is 30.92% lower the current market price of ₹4,989.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹8,281 Cr. market cap, FY2025-2026 high/low of ₹6,739/4,904, reserves of ₹603 Cr, and liabilities of ₹894 Cr.
What is the Market Cap of Procter & Gamble Health Ltd?
The Market Cap of Procter & Gamble Health Ltd is 8,281 Cr..
What is the current Stock Price of Procter & Gamble Health Ltd as on 16 February 2026?
The current stock price of Procter & Gamble Health Ltd as on 16 February 2026 is ₹4,989.
What is the High / Low of Procter & Gamble Health Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Procter & Gamble Health Ltd stocks is ₹6,739/4,904.
What is the Stock P/E of Procter & Gamble Health Ltd?
The Stock P/E of Procter & Gamble Health Ltd is 28.2.
What is the Book Value of Procter & Gamble Health Ltd?
The Book Value of Procter & Gamble Health Ltd is 373.
What is the Dividend Yield of Procter & Gamble Health Ltd?
The Dividend Yield of Procter & Gamble Health Ltd is 2.51 %.
What is the ROCE of Procter & Gamble Health Ltd?
The ROCE of Procter & Gamble Health Ltd is 47.8 %.
What is the ROE of Procter & Gamble Health Ltd?
The ROE of Procter & Gamble Health Ltd is 36.4 %.
What is the Face Value of Procter & Gamble Health Ltd?
The Face Value of Procter & Gamble Health Ltd is 10.0.